21 CFR Part 11 Revision Delayed, But Moves Forward - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

21 CFR Part 11 Revision Delayed, But Moves Forward


INTERPHEX Show Daily

Untitled Document

Interphex, New York, NY (Apr. 24)—Although the second revision of 21 CFR Part 11, the Electronic Records and Signatures Rule, has not been finalized, there is some progress being made. This was the topic of a presentation given by John English, manager of computer system validation for BE&K BioPharm (Newark, DE, www.bek.com) at today’s Interphex Pharmaceutical Manufacturing Conference and Exhibition.

English provided examples of current events by emphasizing the importance of establishing and maintaining electronic record security, maintenance, and backup systems. In these cases, companies lost billions of dollars, had to recall product, received warning letters, or had to shut down operations.

“Electronic data has a big impact on our industry and if you want to know the place where the FDA will go, it’s not only adverse events, it’s your quality assurance records,” says English. “Even if you swear up and down that you only use the paper records and the notebooks, FDA will look at electronic records, and if they find that the test you pasted into the notebook doesn’t exist in the audit trail or the test that should have released the batch is something different than what is in the notebook, then they are going to say that no matter what your policy is, you’re lying.”

As the industry awaits the second revision of the second draft of 21 CFR 11, there is a need to address certain underlying principles. Most notably, the industry must comprehend what is considered “risk-based,” said English. “What does risk-based really mean? What risk-based really should be is, and we forget this sometimes, What is the impact on the patient from the product that you are making in your facility? Our direct impact on the patient is the effect on the product.”

English also emphasized the requirements to comply with the predicate rules. Clarifying what is meant by predicate rules, English said, “What is currently in the good manufacturing practices requires records. Of those, what has FDA placed in the docket that they say they will accept electronic records for.” English gave an example of how Part 11 may be applicable in pharmacies and clinics. “[Part 11] is not supposed to be there, but it’s coming. And it’s the predicate rules that drive it.”

Some of the key areas in the current draft of Part 11 include the definition of the electronic record, definition of an audit trail, electronic copies for inspection, record retention, hybrid and procedural solutions, and the application of electronic signatures. Another area is whether the task force working on the revision should take a quality-based approach or an approach that is enforcement-based, said English.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: INTERPHEX Show Daily,
Click here